IL302098A - Composition and method for treating cancer using a vaccine as a first therapueutic active ingredient in combination with a second active ingredient - Google Patents
Composition and method for treating cancer using a vaccine as a first therapueutic active ingredient in combination with a second active ingredientInfo
- Publication number
- IL302098A IL302098A IL302098A IL30209823A IL302098A IL 302098 A IL302098 A IL 302098A IL 302098 A IL302098 A IL 302098A IL 30209823 A IL30209823 A IL 30209823A IL 302098 A IL302098 A IL 302098A
- Authority
- IL
- Israel
- Prior art keywords
- vaccine
- hpv
- inhibitor
- composition
- immune
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 27
- 239000000203 mixture Substances 0.000 title claims 9
- 206010028980 Neoplasm Diseases 0.000 title claims 8
- 229960005486 vaccine Drugs 0.000 title claims 7
- 239000004480 active ingredient Substances 0.000 title claims 3
- 201000011510 cancer Diseases 0.000 title claims 2
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 claims 8
- 239000003112 inhibitor Substances 0.000 claims 8
- 229960002566 papillomavirus vaccine Drugs 0.000 claims 7
- 230000001225 therapeutic effect Effects 0.000 claims 7
- 235000018102 proteins Nutrition 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 208000000453 Skin Neoplasms Diseases 0.000 claims 5
- 230000003902 lesion Effects 0.000 claims 5
- 201000000849 skin cancer Diseases 0.000 claims 5
- 102000004127 Cytokines Human genes 0.000 claims 4
- 108090000695 Cytokines Proteins 0.000 claims 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 4
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 4
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 4
- 102000014150 Interferons Human genes 0.000 claims 4
- 108010050904 Interferons Proteins 0.000 claims 4
- 102000015696 Interleukins Human genes 0.000 claims 4
- 108010063738 Interleukins Proteins 0.000 claims 4
- 108010008038 Synthetic Vaccines Proteins 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 229950002916 avelumab Drugs 0.000 claims 4
- 229950009791 durvalumab Drugs 0.000 claims 4
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 4
- 229940079322 interferon Drugs 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 108020004999 messenger RNA Proteins 0.000 claims 4
- 229960003301 nivolumab Drugs 0.000 claims 4
- 229960002621 pembrolizumab Drugs 0.000 claims 4
- 229940124551 recombinant vaccine Drugs 0.000 claims 4
- 238000003745 diagnosis Methods 0.000 claims 3
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 2
- 229960004308 acetylcysteine Drugs 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 229960003852 atezolizumab Drugs 0.000 claims 2
- 229940112129 campath Drugs 0.000 claims 2
- 229960000419 catumaxomab Drugs 0.000 claims 2
- 229940121420 cemiplimab Drugs 0.000 claims 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 229940066453 tecentriq Drugs 0.000 claims 2
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims 2
- 229960003862 vemurafenib Drugs 0.000 claims 2
- 208000003200 Adenoma Diseases 0.000 claims 1
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 208000009608 Papillomavirus Infections Diseases 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940000425 combination drug Drugs 0.000 claims 1
- 239000013066 combination product Substances 0.000 claims 1
- 239000008380 degradant Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000000762 glandular Effects 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/876—Skin, melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (31)
1. A method for treating a patient having skin cancer, cancerous tumor, or cancerous lesion, said method comprising administering to the patient, an HPV vaccine which is free of host-cell peptide, polypeptide, or protein or a degradant product thereof in combination with a second active ingredient which is an immune-based therapeutic selected from an Immune Checkpoint Inhibitor, CAR T-cells, N-acetyl cysteine, or mRNA encoding a cytokine.
2. The method of claim 1 wherein the Immune Checkpoint Inhibitor is selected from the group consisting of a Programed Death 1 inhibitor, a Programed Death Ligand inhibitor, and a Cytotoxic T-lymphocyte-Associated Protein 4 inhibitor.
3. The method of claim 2 wherein the Programed Death 1 inhibitor or Programed Death Ligand inhibitor is Cemiplimab, Atezolizumab, Avelumab, Bavencio, Durvalumab, Imfinzi, Keytruda, Nivolumab, Opdivo, Pembrolizumab, or Tecentriq.
4. The method of claim 1 wherein the CAR T-cells are bispecific antibodies or monoclonal antibodies.
5. The method of claim 4 wherein the bispecific antibodies are Catumaxomab.
6. The method of claim 4 wherein the monoclonal antibodies are Campath, Brutuximab, Vismodigib, Vemurafenib, Dabrfenib,or ecorafenib.
7. The method of claim 6 wherein the N-acetyl cysteine administered orally from 600-1200 mg per day.
8. The method of claim 1 wherein the cytokine encoded by mRNA is selected from interleukin, interferon, or granulocyte-macrophage colony-stimulating factor.
9. The method of claim 8 wherein the interleukin is IL-12 or IL-15.
10. The method of claim 8 wherein the interferon is IFN-α
11. The method of claim 1 wherein the HPV vaccine is selected from the group consisting of HPV quadrivalent (types 6, 11, 16, and 18) recombinant vaccine comprising HPV L1 proteins and HPV multivalent (types 16, 18, 31, 33, 45, 52, and 58) recombinant vaccine comprising HPV L1 proteins.
12. The method of claim 1 wherein the vaccine is substantially free of host-cell early antigen, E6 or E7.
13. The method of claim 1 wherein the skin cancer, cancerous tumor, or cancerous lesion is substantially reduced in size or eliminated.
14. The method of claim 1 wherein an effective dose of HPV vaccine is 0.5 ml.
15. The method of claim 1 wherein the cancer or cancerous lesion is selected from the group consisting of squamous cell carcinoma, basal cell carcinoma, melanoma, glandular tumor, and adenoma.
16. The method of claim 1, wherein the patient is 27 years of age or older or is previously not immunized with an HPV vaccine.
17. The method of claim 1 wherein the method further comprises: establishing a positive diagnosis of skin cancer, diagnosis of benign or cancerous tumor, or diagnosis of HPV infection, prior to administering the first dose of HPV vaccine.
18. The method of claim 1, said method comprising administering a dose of an HPV vaccine or immune-based therapeutic directly to a tumor or skin cancer lesion or an area immediately surrounding the tumor, or skin cancer lesion.
19. The method of claim 1 wherein the vaccine or immune-based therapeutic is administered by injection.
20. The method of claim 1 wherein the method comprises administering an immunomodulatory agent or adjuvant to the patient.
21. The method of claim 1 wherein the vaccine and immune-based therapeutic are administered to the patient in a fixed-dose combination product.
22. The method of claim 1, wherein the patient is administered a second dose of vaccine and immune-based therapeutic at least one month following the first administration, and optionally is administered a third dose of vaccine and immune-based therapeutic at least one month following the second administration.
23. A pharmaceutical composition comprising: at least one purified viral L1 protein or fragment thereof; a second active pharmaceutical ingredient which is an immune-based therapeutic selected from an Immune Checkpoint Inhibitor, CAR T-cells and mRNA encoding cytokine; and a pharmaceutically-acceptable carrier.
24. The composition of claim 23 wherein the Immune Checkpoint Inhibitor is selected from the group consisting of a Programed Death 1 inhibitor, a Programed Death Ligand inhibitor, and a Cytotoxic T-lymphocyte-Associated Protein 4 inhibitor.
25. The composition of claim 24 wherein the Programed Death 1 inhibitor or Programed Death Ligand inhibitor is Cemiplimab, Atezolizumab, Avelumab, Bavencio, Durvalumab, Imfinzi, Keytruda, Nivolumab, Opdivo, Pembrolizumab, or Tecentriq.
26. The composition of claim 23 wherein the CAR T-cells are bispecific antibodies which is Catumaxomab or monoclonal antibodies Campath, Brutuximab, Vismodigib, Vemurafenib, Dabrfenib,or ecorafenib.
27. The composition of claim 23 wherein the cytokine encoded by the mRNA is selected from interleukin, interferon, or granulocyte-macrophage colony-stimulating factor.
28. The composition of claim 27 wherein the interleukin is IL-12 or IL-15.
29. The composition of claim 27 wherein the interferon is IFN-α.
30. The composition of claim 23 wherein the HPV vaccine is selected from the group consisting of HPV quadrivalent (types 6, 11, 16, and 18) recombinant vaccine comprising HPV L1 proteins and HPV multivalent (types 16, 18, 31, 33, 45, 52, and 58) recombinant vaccine comprising HPV L1 proteins.
31. The composition of claim 23 wherein the vaccine is substantially free of host-cell early antigen, E6 or E7.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/068,087 US11813329B2 (en) | 2014-10-24 | 2020-10-12 | Method and composition for treating cancer or skin lesion using a vaccine |
PCT/US2021/054622 WO2022081604A1 (en) | 2020-10-12 | 2021-10-12 | Composition and method for treating cancer using a vaccine as a first therapueutic active ingredient in combination with a second active ingredient |
Publications (1)
Publication Number | Publication Date |
---|---|
IL302098A true IL302098A (en) | 2023-06-01 |
Family
ID=81208565
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL302098A IL302098A (en) | 2020-10-12 | 2021-10-12 | Composition and method for treating cancer using a vaccine as a first therapueutic active ingredient in combination with a second active ingredient |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP4225351A1 (en) |
JP (1) | JP2023546073A (en) |
KR (1) | KR20230117106A (en) |
AU (1) | AU2021360676A1 (en) |
CA (1) | CA3195478A1 (en) |
CO (1) | CO2023006083A2 (en) |
CY (1) | CY20232200001T2 (en) |
DE (1) | DE21880926T1 (en) |
DK (1) | DK4225351T1 (en) |
ES (1) | ES2962700T1 (en) |
FI (1) | FI4225351T1 (en) |
HU (1) | HUE21880926T1 (en) |
IL (1) | IL302098A (en) |
MX (1) | MX2023004285A (en) |
PL (1) | PL4225351T1 (en) |
WO (1) | WO2022081604A1 (en) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10162480A1 (en) * | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | The application of mRNA for use as a therapeutic agent against tumor diseases |
US9504657B2 (en) * | 2012-01-12 | 2016-11-29 | Pharmatwob Ltd. | Fixed dose combination therapy of Parkinson's disease |
CA2871774C (en) * | 2012-04-26 | 2021-05-18 | Sentient Lifesciences, Inc. | Use of n-acetylcysteine amide in the treatment of disease and injury |
US10799574B2 (en) * | 2014-10-24 | 2020-10-13 | Hpvvax. Llc | Method and composition for treating cancer or skin lesion using a vaccine |
CA3019149A1 (en) * | 2016-04-01 | 2017-10-05 | Kite Pharma, Inc. | Chimeric antigen and t cell receptors and methods of use |
CA3020330A1 (en) * | 2016-04-07 | 2017-10-12 | Bluebird Bio, Inc. | Chimeric antigen receptor t cell compositions |
-
2021
- 2021-10-12 HU HUE21880926A patent/HUE21880926T1/en unknown
- 2021-10-12 KR KR1020237016232A patent/KR20230117106A/en unknown
- 2021-10-12 MX MX2023004285A patent/MX2023004285A/en unknown
- 2021-10-12 AU AU2021360676A patent/AU2021360676A1/en active Pending
- 2021-10-12 WO PCT/US2021/054622 patent/WO2022081604A1/en active Application Filing
- 2021-10-12 PL PL21880926.7T patent/PL4225351T1/en unknown
- 2021-10-12 CA CA3195478A patent/CA3195478A1/en active Pending
- 2021-10-12 JP JP2023522489A patent/JP2023546073A/en active Pending
- 2021-10-12 DK DK21880926.7T patent/DK4225351T1/en unknown
- 2021-10-12 ES ES21880926T patent/ES2962700T1/en active Pending
- 2021-10-12 DE DE21880926.7T patent/DE21880926T1/en active Pending
- 2021-10-12 FI FIEP21880926.7T patent/FI4225351T1/en unknown
- 2021-10-12 EP EP21880926.7A patent/EP4225351A1/en active Pending
- 2021-10-12 IL IL302098A patent/IL302098A/en unknown
-
2023
- 2023-05-12 CO CONC2023/0006083A patent/CO2023006083A2/en unknown
- 2023-10-19 CY CY20232200001T patent/CY20232200001T2/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2023546073A (en) | 2023-11-01 |
MX2023004285A (en) | 2023-06-19 |
AU2021360676A1 (en) | 2023-06-15 |
WO2022081604A1 (en) | 2022-04-21 |
CY20232200001T2 (en) | 2024-02-16 |
PL4225351T1 (en) | 2023-12-11 |
CO2023006083A2 (en) | 2023-08-18 |
KR20230117106A (en) | 2023-08-07 |
CA3195478A1 (en) | 2022-04-21 |
HUE21880926T1 (en) | 2024-04-28 |
EP4225351A1 (en) | 2023-08-16 |
DK4225351T1 (en) | 2023-10-23 |
ES2962700T1 (en) | 2024-03-20 |
DE21880926T1 (en) | 2024-01-11 |
FI4225351T1 (en) | 2023-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2200634B1 (en) | Targeted interferon demonstrates potent apoptotic and anti-tumor activities | |
Rizza et al. | Role of type I interferon in inducing a protective immune response: perspectives for clinical applications | |
CA2510180A1 (en) | Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2 | |
Geresu et al. | Immunotherapy against cancer: A comprehensive review | |
US20210379143A1 (en) | Drug containing recombinant mistletoe lectins for treating | |
KR20210142663A (en) | Low-dose cytokines co-administered with iRGD to treat cancer | |
EP1276501B9 (en) | Method for treatment of tumors using photodynamic therapy | |
AU2001255740A1 (en) | Method for treatment of tumors using photodynamic therapy | |
IL302098A (en) | Composition and method for treating cancer using a vaccine as a first therapueutic active ingredient in combination with a second active ingredient | |
EP2663324B1 (en) | Combination therapy for treating prostate cancer | |
US20100197595A1 (en) | Treatment of melanoma with alpha thymosin peptides | |
KR101482957B1 (en) | Therapeutic compositions for boosting the effect of antibody therapy against the epidermal growth factor receptor | |
Brzoska et al. | Immunomodulating effects of interferons: conclusions for therapy | |
US20240010740A1 (en) | Combination immunotherapy of il-15 and cd40 agonist in cancer treatment | |
Stull et al. | Current and Emerging Intralesional Immunotherapies in Cutaneous Oncology | |
Kent et al. | Adjuvant therapy in malignant melanoma | |
Kushwaha | Immunomodulators as therapeutic agent | |
Geresu et al. | Immunotherapy against cancer: A comprehensive | |
Nathan et al. | The Immunotherapy of Renal Cell Carcinoma | |
Mashiah et al. | blood flow in the vicinity of melanoma compared to BCC lesions. 9 The number of patients is too small to draw definitive conclusions, but the presence of an erythematous rash in the evolving/escaping melanoma appears to be a pattern. It | |
Geresu et al. | A Review on Immunotherapy against Cancer | |
van Moorselaar et al. | Interferon and Tumor Necrosis Factor in Renal Cell Carcinoma Model Systems |